Crizanlizumab 100 mg/10 mL (10 mg/mL) Suppliers & Bulk Manufacturers
Available Forms: IV Infusion
Available Strengths: 100 mg/10 mL (10 mg/mL)
Reference Brands: Adakveo®(EU & US)
Category: Anemia
Crizanlizumab (Adakveo®) is an FDA- and EMA-approved IV biologic for sickle cell disease, available for B2B pharma distribution in the US and EU to reduce pain crises in affected patients.
Manufacture or export Crizanlizumab? List it or send an offer →
Product Description:
rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.
Crizanlizumab — third party manufacturing & bulk supply
Crizanlizumab 100 mg/10 mL (10 mg/mL) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Crizanlizumab is supplied as IV Infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Crizanlizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Crizanlizumab →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Crizanlizumab is used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. It helps prevent painful crises by decreasing the adhesion of sickled red blood cells and other blood components to blood vessel walls.
It is made from a humanized monoclonal antibody (IgG2) that targets P-selectin, a cell-adhesion protein involved in vaso-occlusion.
The trade name is Adakveo.
It is manufactured by Novartis.
The generic name is Crizanlizumab-tmca.
The brand name is Adakveo.
It is manufactured in various Novartis production facilities, including sites in Europe and the United States.
Related Products
Ferric Carboxymaltose Injection
Strength:
50 mg/mL
Form: Injection
Reference Brands: Injectafer
View Details
Luspatercept
Strength:
25 mg, 75 mg
Form: Lyophilized powder for subcutaneous injection
Reference Brands: Reblozyl
View Details
Ferric Derisomaltose Generics
Strength:
100 mg/ml
Form: IV Infusion
Reference Brands: Monoferric® (U.S.) and Monofer® (EU))
View Details
Eltrombopag Tablet
Strength:
Tablet: 12.5 mg, 25 mg, 50 mg, 75 mg; Suspension:25 mg per packet
Form: Oral Tablets & Oral Powder for Oral Suspension
Reference Brands: Promacta,Revolade
View Details
Deferasirox
Strength:
125 mg, 250 mg, 500 mg
Form: Tablets for Oral Suspension
Reference Brands: Exjade, Jadenu (film-coated)
View Details
Deferoxamine
Strength:
500 mg/vial, 2 g/vial
Form: Lyophilized powder for injection
Reference Brands: Desferal
View Details
Ferumoxytol Injection
Strength:
30 mg/mL
Form: Injection
Reference Brands: Feraheme (USA)
View Details
Epoetin Alfa
Strength:
1,000 IU, 2,000 IU, 4,000 IU, 10,000 IU, 40,000 IU
Form: injection (prefilled syringe)
Reference Brands: EPOGEN (USA), PROCRIT (USA)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
